| Professor Robert Gish
Robert G. Gish, MD, is a hepatologist and medical director of the Liver Transplant Program at the California Pacific Medical Center in San Francisco, California. Dr. Gish is also Associate Clinical Professor of Medicine at the University of Nevada in Reno and Associate Clinical Professor of Medicine at the University of California, San Francisco.
Dr. Gish received his undergraduate training in pharmaceutical sciences at the University of Kansas in Lawrence, Kansas, and his medical degree from the University of Kansas in Kansas City. He completed his internship and residency in internal medicine at the University of California, San Diego, followed by a fellowship in gastroenterology and hepatology at the University of California, Los Angeles.
Dr. Gish is board certified in internal medicine and gastroenterology. He is an active member in many professional associations, including the American Association for the Study of the Liver, the American Gastroenterological Association, the American Society of Transplant Physicians, and the International Liver Transplant Society. He has held several leadership positions for the San Francisco Bay Area Chapter of the American Liver Foundation, serving as executive vice president and chairman of both the medical advisory committee and the public education committee.
As a principal investigator for numerous clinical research programs, Dr. Gish has studied a wide range of treatments for hepatitis and has published extensively in the medical literature on liver disease and transplantation. He has served as a reviewer for major journals in his field, such as the American Journal of Gastroenterology, Journal of Hepatology, Digestive Diseases and Sciences, Liver Transplantation and Surgery, and Transplant Proceedings. He is currently on the editorial board for Gastroenterology & Hepatology and Liver Transplantation. Dr. Gish is a respected lecturer at national and international congresses.
In 2002, Dr. Gish was awarded the Salute to Excellence by the American Liver Foundation.
Professor Gish has disclosed the following information:
 |
Has received grants from Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, GlobeImmune, Inc, InterMune Pharmaceuticals, Inc, Ortho Biotech Products, Ltd, Pfizer Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, and Valeant Pharmaceuticals |
|
Has been a consultant for Amgen Inc, Anadys Pharmaceuticals, Inc, Bayer AG, Bristol-Meyers Squibb Company, Chiron Corporation, Eximias Pharmaceutical Corporation, F. Hoffmann-La Roche Ltd, Gilead Sciences, GlaxoSmithKline, GlobeImmune, Inc, HepaHope, Inc, Human Genome Sciences, Idenix Pharmaceuticals, Innogenetics, InterMune Pharmaceuticals, Inc, Merck & Co., Inc, Metabasis Therapeutics, Inc, Nucleonics, Inc, Ortho Biotech Products, L.P., Pharmasset, Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals, and Zymogenetics, Inc |
|
Has been a speaker for Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, GlaxoSmithKline, Ortho Biotech Products, Ltd, Salix Pharmaceuticals, Inc, Schering-Plough Corporation, and Valeant Pharmaceuticals
|
Professor William Lee
William M. Lee, MD, holds the Meredith Mosle Chair in Liver Disease and is Professor of Internal Medicine at the University of Texas Southwestern Medical School in Dallas. He is also Director of the Clinical Center for Liver Diseases.
Dr Lee received his Doctorate of Medicine from the Columbia University College of Physicians and Surgeons in New York, New York, and completed his internship and residency at the Presbyterian Hospital in New York, New York as well as a fellowship in Liver Diseases as Honorary Registrar to Dr. Roger Williams at Kings College Hospital, London.
He is a consultant to the White House Office of National Drug Control Policy, a consultant to the US FDA OTC Product Advisory Committee. He is Principal Investigator for the Acute Liver Failure Study Group, a national consortium of 23 centers sponsored by the NIH as well as being one of 10 PI’s for the HALT-C Study. He has authored or co-authored nearly 200 peer-reviewed articles, book chapters, and case reports, and lectures widely.
Professor Lee has disclosed the following information:
|
Intends to reference unlabeled/unapproved uses of drugs in his presentation |
|
Has received research support from Idenix Pharmaceuticals, Roche Laboratories, Inc, Schering-Plough Corporation, Siemens Diagnostics, and Vertex Pharmaceuticals, Inc |
Professor Anna Lok
Anna S-F Lok, MD, is Director of Clinical Hepatology and Professor in the Department of Internal Medicine at the University of Michigan Medical Center in Ann Arbor, Michigan.
She received her Doctorate in Medicine from the University of Hong Kong and completed her fellowship in hepatology at the Royal Free Hospital in London, United Kingdom.
Dr Lok has been involved in national organizations in the field of hepatology and has held several leadership positions. She has been an active member of the American Association for the Study of Liver Disease, co-authoring their Practice Guidelines for Chronic Hepatitis B with Dr Brian J. McMahon, and has been a member of the National Board of Directors for the American Liver Foundation. She has also served as Associate Editor for the journal Hepatology, and currently serves as an editor of Journal of Viral Hepatitis.
Her research interests include the study of hepatitis B virus mutations, new antiviral therapies for hepatitis B, liver transplantation for hepatitis B, and the natural history of hepatitis B. She has authored more than 200 peer-reviewed articles in the field of hepatology, with a focus on hepatitis B, and has given invited lectures on hepatitis B all over the world.
Professor Lok has disclosed the following information:
|
Intends to reference unlabeled/unapproved uses of drugs in her presentation |
|
Has received grants from Bristol-Myers Squibb Company, Gilead Sciences, and Idenix Pharmaceuticals |
|
Has received honoraria from Bristol-Myers Squibb Company and Gilead Sciences |
Professor Robert Perrillo
Robert Perrillo, MD, is Associate Director of Hepatology and Coordinator of the Transplant Hepatology Program at Baylor University Medical Center in Dallas, Texas. He graduated from Georgetown University School of Medicine in Washington, DC, and completed his medical residency and a fellowship in gastrointestinal medicine at Barnes Hospital, Washington University School of Medicine, in St. Louis, Missouri. Prior to his current appointment, Dr. Perrillo was Professor of Medicine at Washington University and Director of the Gastroenterology Section of the St. Louis Veterans Affairs Medical Center; Section Head for Gastroenterology and Hepatology at the Ochsner Clinic Foundation in New Orleans, Louisiana; and Director of Academic Affairs, Section of Gastroenterology and Hepatology at the Ochsner Clinic. During his extensive career he has played a strategic role in the activities of the American Association for the Study of Liver Diseases.
Dr. Perrillo has published more than 190 papers on viral hepatitis in numerous journals, including Gastroenterology, Hepatology, and The New England Journal of Medicine. He is internationally recognized for his work in antiviral therapy for chronic hepatitis B. He has been a prominent international speaker and opinion leader in this field and is one of only two US physicians on the editorial board of Journal of Hepatology. Dr. Perrillo has had extensive experience with interferon and nucleoside analogs as therapy for hepatitis B. He is currently the principal investigator for clinical research programs on the combined use of interferon and nucleoside analog treatment of chronic hepatitis B as well as for studies of several nucleoside analogs in various phases of development.
Professor Perrillo has disclosed the following information:
|
Intends to reference unlabeled/unapproved uses of drugs in his presentation |
|
Has received honoraria from Bristol-Meyers Squibb Company, Idenix Pharmaceuticals, Idenix Pharmaceuticals/Novartis Pharmaceutical Corp, and Roche Laboratories, Inc |
|
Has been a speaker for Bristol-Meyers Squibb Company, Idenix Pharmaceuticals, and Roche Laboratories, Inc |
|
Has been on advisory boards for Idenix Pharmaceuticals/Novartis Pharmaceutical Corp and Roche Laboratories, Inc |
Professor David Thomas
David L. Thomas, MD, is Chief of the Division of Infectious Diseases in the Department of Medicine at the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Professor of Medicine and Epidemiology at the Johns Hopkins University School of Medicine and Hygiene and Public Health in Baltimore. He is also affiliated with The Johns Hopkins Hospital.
Dr. Thomas received his Doctorate of Medicine from the West Virginia University School of Medicine in Morgantown, West Virginia, and received a Masters degree in Public Health from the Johns Hopkins School of Hygiene and Public Health. He completed his internship and residency at the Wake Forest University School of Medicine in Winston-Salem, North Carolina, and his fellowship in infectious diseases at the Johns Hopkins University School of Medicine.
He is a member of the American Society for Clinical Investigation and the American Association for the Study of Liver Disease, among other organizations, and is a fellow of the Infectious Diseases Society of America. Dr Thomas has been a principal investigator in a number of trials dealing with the spread of hepatitis C, and has authored or co-authored more than 180 peer-reviewed articles, invited editorials, and book chapters. He is a frequently invited guest to lecture on hepatitis and HIV throughout the world.
Professor Thomas has disclosed the following information:
|
Intends to reference unlabeled/unapproved uses of drugs or products in his presentation |
|
Does not have any relevant financial relationships with any commercial interests |
Professor Naoky Tsai
Naoky C. Tsai, MD, is Professor of Medicine and Chief of the Section of Hepatobiliary Disease in the Department of Medicine at the John A. Burns School of Medicine in Honolulu, Hawaii. In addition, he serves as Medical Director of the Liver Center and the Liver Transplant Program at Hawaii Medical Center–East in Honolulu.
Dr Tsai received his Doctorate in Medicine from Taipei Medical University in Taipei, Taiwan and completed his internship and residency at the Yale University Affiliated Residency Program in New Haven, Connecticut. He completed his fellowship in gastroenterology at the State University of New York in Buffalo.
Throughout his career Dr Tsai has led numerous clinical trials evaluating therapies for chronic hepatitis. He is well-published in the medical literature. A lecturer worldwide, Dr Tsai has offered grand rounds and featured presentations at major association meetings in his field. Dr Tsai is a member of the American Association for the Study of Liver Diseases, having served on the Abstract Review Group, and of the American Gastroenterological Association, among other organizations. He was a member of the steering committee of the US–Japan Autoimmune Liver Disease Association. Dr Tsai became a UNOS-certified transplant hepatologist in 2002. He is board-certified in internal medicine and gastroenterology. In March 2007 he was presented a Lifetime Achievement Award by the American Liver Foundation in Hawaii for his effort in educating and promoting liver heath in that state.
Professor Tsai has disclosed the following information:
|
Has received honoraria from Bristol-Myers Squibb Company, Gilead Sciences, Idenix Pharmaceuticals/Novartis Pharmaceutical Corp, and Roche Laboratories, Inc |
|
Has acted as a speaker for Bristol-Myers Squibb Company, Gilead Sciences, Idenix Pharmaceuticals/Novartis Pharmaceutical Corp, and Roche Laboratories, Inc |
Professor Lory Wiviott
Dr. Wiviott is chairman of medicine at California Pacific Medical Center in San Francisco. He is also assistant clinical profess or of medicine at the University of California San Francisco Medical Center. Dr. Wiviott received his medical degree from the Albert Einstein College of Medicine in New York. He completed his residency training at Columbia Presbyterian Medical Center-College of Physicians and Surgeons in New York, and, following this, was a research assistant in infectious diseases with Memorial Sloan Kettering Cancer Center. He completed a fellowship in infectious diseases and was a visiting postdoctoral fellow in cancer research at the University of California, San Francisco Medical Center, prior to his current faculty appointments.
Dr. Wiviott has published and lectured extensively on the management of various types of infectious disease. He is a member of the Infectious Diseases Society of America and the HIV Medicine Association. Among his many honors and awards are his listings in Best Doctors in America, Best Doctors in the Bay Area, and Who’s Who in Healthcare & Medicine.
Professor Wiviott has disclosed the following information:
|
Has received honoraria from Cubist Pharmaceuticals, Inc, Ortho-McNeil Pharmaceutical, Inc, and Pfizer Inc |
Professor Richard Proctor
Professor Proctor has disclosed the following information:
|
Has received grant support and acted as an investigator for Cubist Pharmaceuticals and Kimberley-Clark |
|
Has received honoraria from Biosynexus, Inc |
|
Has acted as a speaker for Aventis Pharmaceuticals Inc, Pfizer Inc, and Wyeth Pharmaceuticals |
Course Format
The participant should first read the flow chart, then complete and submit the post-test and evaluation form to the address on the post-test. This entire process should take the participant 1.5 hours to complete.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Wisconsin School of Medicine and Public Health and MDG Development Group, LLC. The University of Wisconsin School of Medicine and Public Health is accredited by the ACCME to provide continuing medical education for physicians.
This CME activity is jointly sponsored by the University of Wisconsin School of Medicine and Public Health and MDG Development Group. |
